Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.95
+0.05 (0.16%)
Jan 22, 2026, 1:35 PM CST
5.34%
Market Cap5.88B
Revenue (ttm)3.35B
Net Income (ttm)345.57M
Shares Out190.20M
EPS (ttm)1.81
PE Ratio17.07
Forward PEn/a
Dividend0.95 (3.08%)
Ex-Dividend DateJul 11, 2025
Volume186,538
Average Volume176,363
Open30.95
Previous Close30.90
Day's Range30.75 - 31.05
52-Week Range25.95 - 32.60
Beta0.13
RSI57.48
Earnings DateMar 20, 2026

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1977
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1734
Full Company Profile

Financial Performance

In 2024, Sinphar Pharmaceutical's revenue was 3.15 billion, an increase of 6.33% compared to the previous year's 2.96 billion. Earnings were 304.71 million, a decrease of -18.78%.

Financial Statements